Over the horizon: early stage trials for NASH
Another dozen or so drugs are in early stage trials. Most notably, VBL Therapeutics is currently testing lecinoxoids VB 201 and VB 703, antagonists for Toll-like receptors 2 and 4 (TLR-2 and TLR-4), which play a role in nonalcoholic fatty liver disease.
In an exploratory trial, VB 201 demonstrated significant reduction of vascular inflammation, suggesting that lecinoxoids can restrict liver inflammation and ameliorate liver fibrosis.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest